Multiple sclerosis (MS) affects more than 2.1 million people worldwide and is the most common cause of non-traumatic chronic neurological disability in young and middle-aged adults.
Dalfampridine Extended Release Tablets-Clinical Need and Use
Multiple sclerosis (MS) affects more than 2.1 million people worldwide and is the most common cause of non-traumatic chronic neurological disability in young and middle-aged adults.
1,2 MS is associated with a considerable economic burden from medical costs and lost productivity.
MS presents patients with many challenges, among which walking impairment is one of the most serious. Walking impairment is most prevalent in patients who have had progressive MS for many years, but subtle changes in walking and gait may be discerned even in patients with recent disease onset. 3 These may not be apparent to observers, including healthcare providers, and may not be detectable in a routine physical examination. Decreased walking ability is regarded by most MS patients as the worst consequence of MS and has the most serious impact on their ability to continue in employment and to participate in leisure and social activities. 4, 5 Therefore medications that can help restore walking ability in MS are greatly needed. in January, 2010, and was the first drug approved for this indication. 2, 7 Dalfampridine is also known by its previous US Adopted Name (USAN) and current International Nonproprietary Name (INN), 'fampridine', as well as its chemical name '4-aminopyridine' (4-AP).
The purpose of this article is to discuss the clinical need for a treatment to improve walking ability in MS. The discussion will consider the extent to which dalfampridine fulfills this need and how the expectations of patients receiving dalfampridine can be managed.
The Need for Treatments of Walking Impairment in Multiple Sclerosis
As MS progresses, patients face increasing mobility impairment in the course of their disease. Reviewing the natural history of untreated MS
indicates that some degree of walking impairment is likely to occur by eight years, a walking stick or cane is often needed by 15 years, and patients are usually confined to a wheelchair by 25-30 years.
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Until recently, no medication was approved to improve walking, although sometimes medications approved for the treatment of spasticity (e.g. baclofen and tizanidine) could be helpful. The only other treatments available until now have been rehabilitation, physiotherapy, exercise programs, use of a hip flexion orthosis, and electrical stimulation. [13] [14] [15] [16] Physical treatments have been shown to play an important role in symptom management, but as of yet there has been insufficient research in this area. A randomized controlled trial is currently in progress to determine which form of physical activity optimizes outcome for MS patients. 17 Large numbers of patients with MS have differing levels of walking impairment and their abilities are likely to progressively decline. Therefore, there is a need for drug therapies in the treatment of walking impairment in MS.
Dalfampridine-A New Treatment for Walking Impairment in Multiple Sclerosis

History and Clinical Use
The active component of dalfampridine is 4-AP, which binds reversibly to potassium channels on neurons, blocking the ion conductance pathway.
This blockade leads to the prolongation of action potentials in unmyelinated nerve fibers, increased transmitter release at synaptic endings and improved conduction in demyelinated nerve fibers. 
AE = adverse event; MS = multiple sclerosis; MSWS-12 = 12-Item Multiple Sclerosis Walking Scale; OL = open label; PRMS = progressive-relapsing multiple sclerosis; PPMS = primary-progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary-progressive multiple sclerosis; T25FW = Timed 25-Foot Walk; UTI = urinary tract infection.
(SR) technology for 4-AP enabled lower and more stable plasma levels with twice daily dosing, and resulted in the first clinical trials of the drug in MS that showed a significant improvement in timed ambulation. 23 The current oral formulation of dalfampridine is an extended release matrix containing 10mg of active ingredient. 27 Clinician Global Impression (CGI), and Subject Global Impression (SGI). The design and results of these trials are summarized in Table 1 .
The primary objective of the phase II trial (MS-F201) was to determine the tolerability of escalating doses of dalfampridine from 10 to 40mg twice daily. While the study demonstrated an increase in lower-extremity muscle strength and walking speed, two patients experienced seizures, one at 30mg twice daily, the other at 35mg twice daily.
Discontinuations due to adverse events occurred at doses of 25mg and higher. Therefore, subsequent studies concentrated on evaluating doses in the range of 10-20mg. 28 A follow-up phase II trial, (MS-F202) determined the optimal dose (10mg twice daily) and concluded that the T25FW was an appropriate response criterion. 29 The pivotal MS-F203 trial (a phase III study involving 301 patients with all four types of MS), demonstrated that dalfampridine improved walking speed as measured by the prospectively-defined responder rate. A responder was defined as a patient who showed faster walking speed for at least three of four 'on-drug' visits than the fastest speed achieved among five 'off-drug' visits. The effect was maintained over 14 weeks. with primary-progressive MS, and 3.0% had progressive-relapsing MS.
Timed walk response was markedly improved for patients receiving dalfampridine 10mg compared with placebo, regardless of disease progression, duration of disease or EDSS score as shown by odds ratios for these parameters plotted in Figure 1 . [32] [33] [34] The average improvement in walking speed among timed walk responders was 25.3% (range 3.9-110.4%). Responders also showed significantly reduced MSWS-12 scores (indicating improvement), significantly improved CGI and SGI scores, and significant improvements over placebo in lower-extremity muscle strength and Ashworth score (see Figure 2) .
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More 
dalfampridine-treated than placebo patients had increases in walking speed of ≥20, ≥30 and, ≥40%, moving from restricted (household) mobility (walking speed <1.3ft/s) to full community mobility (walking speed >2.6ft/s). 34 These community ambulation categories were originally developed for assessing stroke patients. 36 No dalfampridine responders showed a decline in this ability (see Table 2 ). 34 However, not all patients receiving dalfampridine showed improvements in walking ability. The mean effect was small, since 35-43% of people had a consistent response to treatment, but that group experienced meaningful change. In general, the greater the increase in walking speed, the smaller the proportion of patients achieving it. For example, 54.1% of patients showed an improvement in walking speed of ≥10% but only 31.5% showed an improvement of ≥20%. 37 
An interim analysis of two open-label extension studies (MS-F203EXT
and MS-F204EXT) has recently been presented. Patients were assessed at two, 14, and 26 weeks, and every six months up to 2.5 years.
The walking speed of patients who continued on dalfampridine from the double-blind trial remained above baseline whereas those not on dalfampridine fell below that level. The response tended to drop back to baseline for patients continuing on dalfampridine at 2.5 years in MS-F203EXT and at 1.2 years in MS-F204EXT. 38 
Safety Data
The safety analysis population for the combined studies included 638
patients. The profile of adverse effects was consistent over all three studies. The most common adverse effects were falls, urinary tract infections (UTI), insomnia, asthenia, dizziness, headaches, nausea, and back pain, which were mostly mild to moderate and transient in nature (see Table 3 ). 37 In the treatment group, 2.8% of patients withdrew from the study because of adverse effects compared with 2.1% in the placebo group. Falls were seen at similar levels across treatment and placebo group patients, but UTIs were slightly more frequent with dalfampridine. These findings are consistent with previous safety results shown in clinical studies using dalfampridine.
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The incidence of seizures was the biggest safety concern in these trials, since earlier studies indicated that dalfampridine had a narrow toxic-therapeutic ratio. 39 However, those studies did not use extended No new adverse effects have been noted. 40 The incidence of MS relapse was low in the pooled treatment (5.3%) and placebo groups (3.8%). Post-treatment, the incidence of relapse was higher in the treatment group than the placebo group (1.8 versus 0.4%). 41 Cases of unintentional overdose of compounded 4-AP in MS have been reported 42 and seizures can occur with overdose of both the immediate and extended-release formulations. 28, 43 Overall, dalfampridine is well tolerated. However, it is contraindicated in patients with a history of seizures and in those with moderate or severe renal impairment. A risk evaluation and mitigation strategy (REMS) program, involving a detailed medication guide that stresses the necessity for adherence to the 10mg twice-daily dosage, is now available.
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Managing Expectations of Dalfampridine in Multiple Sclerosis Patients
Any medication that offers improvements in walking in MS will be of great interest to patients and may raise hopes of restoring lost mobility.
However, patient expectations of dalfampridine could be too high and it is critical that patients have a realistic view. Dalfampridine provides Unrealistic expectations of disease modifying therapies (DMTs) have been previously shown to result in poor treatment adherence, and a perceived lack of efficacy accounts for 30 to 52% of discontinuations of DMTs. 45, 46 Among patients receiving IFNβ therapy in one study, 57% of patients had unrealistic expectations regarding reduction in attack rate and 34% regarding improvement in functional status before the initiation of therapy. Education reduced these figures, but following this education, expectations remained high and were significantly related to the discontinuation of therapy within six months. 47 In addition, depression and flu-like symptoms were also found to be associated with the discontinuation of therapy.
Previous studies have shown that managing patient expectations and maintaining good communications between healthcare providers and patients can improve adherence to DMT and, consequently, improve outcomes. 48, 49 Self-efficacy, self-esteem, and hope have been reported as predictors of adherence to DMT. 50 Therefore it is important to maintain an open and trusting relationship between patients and healthcare providers. Understanding of and empathy for the patient's fears, expectations, and health beliefs are crucial. Healthcare providers should
give patients the necessary information for them to make informed decisions regarding the available treatment options and should monitor and counsel them throughout treatment. In the case of dalfampridine, patients could be prescribed this drug for a number of years; therefore it will be critical to ensure that only those patients who respond to treatment and tolerate it well receive longer-term dalfampridine therapy.
Conclusion and Future Developments
Dalfampridine 
